ORAL DRUG DELIVERY ARTICLES
Need A Drug Delivery Conversation Starter? Try Target Product Profile
In this article, Chief Editor Tom von Gunden explores the need for and existence of cross-functional communication during drug product development and delivery device selection. He consults industry veterans with experience in various formulation or delivery roles at GSK and Merck. They identify the Target Product Profile (TPP) as the core concept guiding collaboration.
ORAL DRUG DELIVERY RESOURCES
-
Combination products provide significant avenues for increasing patient adherence and overall efficacy. This collection outlines the opportunity and identifies strategies for gaining regulatory approval.
-
Medication acceptance and adherence are critical concerns in pediatric populations due to these patients’ rapid anatomical and physiological development.
-
This paper presents three approaches to address poor solubility in organic solvents for spray drying as well as case studies outlining their successful application during development.
-
Drugs have become more lipophilic and complex in structure over time. Innovative strategies are needed to improve the bioavailability of these new drugs.
-
Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment to offer improved patient comfort and adherence while expanding the therapeutic market.
-
Understanding the properties of ASDs and their relationship to the downstream product scale up, stability, and in-vivo performance is critical to successfully utilize them for drug delivery of insoluble drugs.
-
Improper drug solubility can lead to suboptimal drug delivery and absorption, resulting in ineffective drug efficacy and side effects, so solubility must be evaluated in the early stages of drug discovery.
ORAL DRUG DELIVERY SOLUTIONS
-
Our platform improves bioavailability, enables higher drug loads, optimizes delivery routes, and enhances formulation performance for small and large molecules across diverse therapeutic applications.
-
Multiparticulates enable tailored drug release with improved flexibility, dose accuracy, and patient convenience, leveraging technologies like Diffucaps® for customized profiles including immediate, delayed, extended, and pulsatile delivery.
-
As the number of poorly soluble compounds continues to increase in the industry development pipeline, conventional formulation strategies may not be sufficient to achieve acceptable levels of solubility in the gastrointestinal tract and hence absorption into the systemic circulation.
-
Learn what oral modified-release (MR) dosage forms can offer and why they continue to rise in popularity.
-
Adare Pharma Solutions provides end-to-end CDMO services for oral solid dose drugs, enabling efficient development, manufacturing, and packaging with advanced technologies and global scale.
-
Battelle, a leading nonprofit in applied science and technology, drives innovation in national security, healthcare, environment, and education while managing research labs and advancing critical discoveries.
-
A new six-phase assessment process simplifies regulatory approval for generic drug-device combination products, reducing costs and timelines while maintaining safety, effectiveness, and substitutability with reference-listed drugs.
-
AustinPx offers integrated GMP manufacturing services for oral dosage forms with a full complement of analytical development and testing capabilities.
-
This comprehensive suite of services encompasses the entire spectrum of user research, starting from the conceptualization of study designs to meticulous data analysis and comprehensive reporting.
-
Developing an optimized formulation tailored to your API nanoparticles is critical to unlocking their full potential.